UG's Cosmetic Sales Plunge, Bets on Sexual Wellness & 'Green' Products

TL;DR

**UG is ditching its declining cosmetic cash cow to chase the sexual wellness boom, a risky but potentially lucrative pivot.**

AI Summary

UNITED GUARDIAN INC (UG) reported a significant shift in its revenue streams for the fiscal year ended December 31, 2025. Sales of cosmetic ingredients plummeted to approximately 29% of total sales in 2025, a sharp decline from 45% in 2024, indicating a substantial decrease in this segment's contribution. The company is actively developing new products, particularly focusing on 'natural' and 'preservative-free' versions of its Lubrajel line, and has expanded its COSMOS-certified offerings. A key strategic move in January 2026 was entering a new distribution agreement with Brenntag Specialties for its new Natrajel line of sexual wellness ingredients in North America and for Lubrajel and Natrajel products in France, signaling an anticipated entry into the sexual wellness market. The company also renegotiated its distribution agreement with Azelis Group NV for South Korea in February 2025, replacing Ashland Specialty Ingredients in that region. While specific net income figures are not provided in the excerpt, the substantial decline in cosmetic ingredient sales suggests potential pressure on overall profitability. Risks include pricing pressure from low-cost competitors in the cosmetic ingredients market, which the company aims to counter with innovation and quality.

Why It Matters

UNITED GUARDIAN INC's strategic pivot away from a heavy reliance on cosmetic ingredients, evidenced by a 16 percentage point drop in its contribution to total sales, signals a significant shift for investors. The company's aggressive move into sexual wellness ingredients with the Natrajel line and expanded distribution through Brenntag Specialties could open new revenue streams, but also introduces new market risks and competitive landscapes. For employees, this shift may mean new R&D priorities and manufacturing demands. Customers in the cosmetic sector might see changes in distribution partners, while new customers in the sexual wellness market will encounter UG's innovative hydrogel formulations. This repositioning reflects broader market trends towards natural and specialized products, potentially impacting competitors like Ashland, Inc. and Croda International Plc. by intensifying competition in niche segments.

Risk Assessment

Risk Level: medium — The company faces medium risk due to significant pricing pressure from low-cost competitors in its cosmetic ingredients segment, which saw its contribution to total sales drop from 45% in 2024 to 29% in 2025. While UG is innovating with 'natural' products and entering the sexual wellness market, the success of these new ventures is unproven and subject to market acceptance and intense competition.

Analyst Insight

Investors should closely monitor the sales performance of UNITED GUARDIAN INC's new Natrajel sexual wellness line and the impact of its new distribution agreements in 2026. Evaluate whether the growth in these new segments can offset the declining contribution from cosmetic ingredients and provide a clear path to sustained revenue and profit growth.

Revenue Breakdown

Key Numbers

• 29% — Cosmetic Ingredients Sales Percentage (Percentage of total sales for the year ended December 31, 2025, down from 45% in 2024.)
• 45% — Cosmetic Ingredients Sales Percentage (Percentage of total sales for the year ended December 31, 2024, indicating a significant decline in 2025.)
• $8.00 — Common Stock Closing Price (Price per share used to compute market value of non-affiliate equity as of June 30, 2025.)
• 1942 — Founding Year (Year United International Research, Inc. (predecessor entity) was founded.)
• 2026-01 — New Distribution Agreement Date (Month and year UNITED GUARDIAN INC entered into a new distribution agreement with Brenntag Specialties.)

Key Players & Entities

• UNITED GUARDIAN INC (company) — Registrant
• Brenntag Specialties (company) — new distribution partner for Natrajel and Lubrajel products
• Ashland Specialty Ingredients (company) — largest cosmetic ingredients distributor, renegotiating agreement
• Azelis Group NV (company) — new marketing and distribution partner for South Korea, also in UK and Ireland
• Dr. Alfred R. Globus (person) — Founder and former Chairman and Director of Research
• Guardian Laboratories (company) — division manufacturing and developing products
• $36,754,552 (dollar_amount) — aggregate market value of common equity held by non-affiliates as of June 30, 2025
• 4,594,319 (dollar_amount) — shares of Common Stock outstanding as of March 1, 2026
• Sederma SAS (company) — cosmetic ingredient distributor in France
• Safic-Alcan S.p.A. (company) — cosmetic ingredient distributor in Italy

FAQ

Risk Factors

• Competition in Cosmetic Ingredients [medium — market]: The company faces pricing pressure from low-cost competitors in the cosmetic ingredients market. This is a significant risk given the substantial decline in this segment's contribution to total sales.
• Dependence on Product Innovation [medium — market]: The company's business model relies heavily on product innovation and development of new products with unique properties. Failure to innovate or develop products that meet evolving market needs, such as 'natural' and 'preservative-free' options, could impact future growth.
• Reliance on Contract Manufacturing [low — operational]: While most products are manufactured in-house, the urological product Renacidin is manufactured by an outside contract manufacturer. Any disruption or quality issues with this third-party supplier could impact product availability.

Industry Context

The specialty ingredients market, particularly for cosmetics and personal care, is increasingly driven by consumer demand for natural, sustainable, and preservative-free products. Companies are investing in R&D to meet these evolving preferences and obtain certifications like COSMOS. The sexual wellness market is also experiencing growth, with new entrants and established players seeking to capture market share through innovative product offerings.

Regulatory Implications

The company's focus on COSMOS-certified products suggests an awareness of and adherence to evolving regulatory and consumer-driven standards in the natural and organic cosmetics sector. Expansion into sexual wellness ingredients may also involve navigating specific product safety and marketing regulations within that category.

What Investors Should Do

1. Monitor the performance of the new Natrajel line and the Brenntag distribution agreement.
2. Track the revenue contribution and growth of the 'natural' and 'preservative-free' Lubrajel variants.
3. Analyze the impact of the Azelis Group NV distribution agreement in South Korea.
4. Evaluate the company's ability to innovate and maintain its market position against low-cost competitors.

Key Dates

• 2025-02-XX: Renegotiated distribution agreement with Azelis Group NV for South Korea. — This strategic move replaced Ashland Specialty Ingredients, potentially opening new avenues for sales in the South Korean market.
• 2026-01-XX: Entered new distribution agreement with Brenntag Specialties. — This agreement signals entry into the sexual wellness market with the new Natrajel line in North America and expands distribution for Lubrajel and Natrajel in France, indicating a strategic pivot and growth initiative.

Glossary

COSMOS-certified

A certification standard for organic and natural cosmetics, ensuring adherence to strict guidelines regarding ingredients and manufacturing processes. (The company's expansion of COSMOS-certified offerings indicates a strategic focus on meeting the growing demand for natural and sustainable cosmetic ingredients.)

Lubrajel

A proprietary line of specialty ingredients developed by United-Guardian, Inc., often used in personal care and cosmetic applications. (The focus on developing new versions of Lubrajel, including 'natural' and 'preservative-free' options, highlights the company's R&D efforts to adapt to market trends.)

Natrajel

A new line of sexual wellness ingredients developed by United-Guardian, Inc. (The distribution agreement for Natrajel signifies the company's strategic entry into the sexual wellness market, a new and potentially significant revenue stream.)

Guardian Laboratories

The division of United-Guardian, Inc. responsible for manufacturing, marketing, and developing specialty ingredients and healthcare products. (This division is central to the company's operations, producing cosmetic, personal care, sexual wellness ingredients, and healthcare products.)

Year-Over-Year Comparison

The most significant change compared to the previous filing is the dramatic decline in the contribution of cosmetic ingredients to total sales, falling from 45% in 2024 to 29% in 2025. This indicates a substantial shift in the company's revenue mix. While specific financial metrics like net income are not detailed here, this revenue shift suggests potential pressure on overall profitability. New strategic initiatives, such as the entry into the sexual wellness market with the Natrajel line and expanded distribution agreements, are key developments aimed at future growth and diversification.

Key Financial Figures

• $0.10 — ange on which registered Common Stock, $0.10 par value UG The NASDAQ Global Mark
• $8.00 — 36,754,552 (based on a closing price of $8.00 per share). (For the purpose of this re

Filing Documents

• ug20251231_10k.htm (10-K) — 891KB
• ex_931545.htm (EX-31.1) — 12KB
• ex_931546.htm (EX-31.2) — 14KB
• ex_931547.htm (EX-32) — 9KB
• grassisig.jpg (GRAPHIC) — 6KB
• 0001171843-26-001973.txt ( ) — 5195KB
• ug-20251231.xsd (EX-101.SCH) — 49KB
• ug-20251231_def.xml (EX-101.DEF) — 319KB
• ug-20251231_lab.xml (EX-101.LAB) — 290KB
• ug-20251231_pre.xml (EX-101.PRE) — 350KB
• ug-20251231_cal.xml (EX-101.CAL) — 50KB
• ug20251231_10k_htm.xml (XML) — 719KB

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 16 Item 1B. Unresolved Staff Comments 16 Item 1C. Cybersecurity 16 Item 2.

Properties

Properties 17 Item 3.

Legal Proceedings

Legal Proceedings 17 Item 4. Mine Safety Disclosures 17 Part II 17 Item 5. Market for Registrant ' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 17 Item 6. [Reserved] 18 Item 7. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 24 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 24 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 24 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 24 Item 9A.

Controls and Procedures

Controls and Procedures 24 Item 9B. Other Information 25 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 25 Part III 25 Item 10. Directors, Executive Officers and Corporate Governance 25 Item 11.

Executive Compensation

Executive Compensation 25 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 25 Item 13. Certain Relationships and Related Transactions and Director Independence 25 Item 14. Principal Accountant Fees and Services 25 Part IV 26 Item 15. Exhibits and Financial Statement Schedules 26

Signatures

Signatures 26 4 PART I Item 1.

Business

Business Overview United-Guardian, Inc. ("Company") is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients and a line of healthcare products including pharmaceuticals and medical lubricants. We conduct various research and development ("R&D") activities. Our R&D department primarily develops new and unique specialty cosmetic and sexual wellness ingredients. We develop new products using natural and environmentally friendly raw materials, which is a priority for many of our cosmetic customers. The R&D department also modifies, refines, and expands the uses for existing products, with the goal of further developing the markets that our products are used in. All the products that we market, except for Renacidin , are produced at our facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for us by an outside contract manufacturer. Our predecessor entity, United International Research, Inc. ("UIR"), was founded and incorporated in New York in 1942 by Dr. Alfred R. Globus, our Chairman and Director of Research until his death on April 9, 2009. On February 10, 1982, a merger took place between UIR and Guardian Chemical Corporation ("Guardian"), an affiliate of UIR, whereby Guardian was merged into UIR and the name was changed to United-Guardian, Inc., a New York corporation. On September 14, 1987, United-Guardian, Inc., a New York corporation, was merged with and into a newly formed Delaware corporation by the same name, United-Guardian, Inc., for the purpose of changing the domicile to the State of Delaware. The cornerstone of our business is our product innovation. We use our product development and formulation expertise to maintain our market position and to propel future growth. We also focus on the development of new products that fill unmet market needs and have unique properties. Our products are sold into stable

View Full Filing

View this 10-K filing on SEC EDGAR